Marker Therapeutics, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Marker Therapeutics, Inc. has filed its 2023 10-K annual report detailing financial data and corporate history.</b>

AI Summary

Marker Therapeutics, Inc. (MRKR) filed a Annual Report (10-K) with the SEC on March 26, 2024. Marker Therapeutics, Inc. filed its 10-K report for the fiscal year ending December 31, 2023. The company's principal business address is 4551 Kennedy Commerce Dr., Houston, TX 77032. Marker Therapeutics was formerly known as TAPIMMUNE INC. and GENEMAX CORP. The filing includes data related to common stock, additional paid-in capital, and retained earnings for fiscal years 2021, 2022, and 2023. Information regarding equity incentive plans and stock options for employees and non-employees is detailed.

Why It Matters

For investors and stakeholders tracking Marker Therapeutics, Inc., this filing contains several important signals. This filing provides a comprehensive overview of the company's financial position and operational history for the fiscal year 2023, crucial for investors assessing its performance and future prospects. The inclusion of historical company names and details on equity plans offers context for understanding the company's evolution and compensation structures.

Risk Assessment

Risk Level: medium — Marker Therapeutics, Inc. shows moderate risk based on this filing. The filing is a standard 10-K, which is a routine annual report. However, the lack of specific financial performance metrics like revenue or net income in the provided snippet limits a deeper risk assessment.

Analyst Insight

Investors should review the full 10-K filing to understand the company's financial health, operational strategies, and any disclosed risks.

Key Numbers

• 20231231 — Fiscal Year End (Conformed period of report)
• 20240326 — Filing Date (Filed as of date)
• 2834 — Standard Industrial Classification (Pharmaceutical Preparations)

Key Players & Entities

• Marker Therapeutics, Inc. (company) — Filer name
• TAPIMMUNE INC. (company) — Former company name
• GENEMAX CORP (company) — Former company name
• 4551 KENNEDY COMMERCE DR. (company) — Business address street
• HOUSTON (company) — Business address city
• TX (company) — Business address state
• 77032 (company) — Business address zip

FAQ

Industry Context

Marker Therapeutics, Inc. operates in the pharmaceutical preparations industry.

Regulatory Implications

The filing is a standard SEC Form 10-K, required for publicly traded companies in the United States.

What Investors Should Do

1. Review the full 10-K for detailed financial statements and management discussion.
2. Analyze the company's equity structure and incentive plans.
3. Investigate any disclosed risk factors and their potential impact.

Year-Over-Year Comparison

This is the 2023 10-K filing, providing updated annual information compared to previous filings.

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar
• $3.10 — ter) based on the closing sale price of $3.10 as reported on the Nasdaq Capital Marke
• $2 million — the FDA Orphan Products Grant program ($2 million), NIH Small Business Innovation Researc
• $13 million — and Research Institute of Texas (CPRIT, $13 million), to support the Phase 2 clinical trial

Filing Documents

• mrkr-20231231x10k.htm (10-K) — 1995KB
• mrkr-20231231xex4d0.htm (EX-4.0) — 6KB
• mrkr-20231231xex4d1.htm (EX-4.1) — 21KB
• mrkr-20231231xex10d8.htm (EX-10.8) — 172KB
• mrkr-20231231xex10d9.htm (EX-10.9) — 120KB
• mrkr-20231231xex21d1.htm (EX-21.1) — 2KB
• mrkr-20231231xex23d1.htm (EX-23.1) — 2KB
• mrkr-20231231xex31d1.htm (EX-31.1) — 12KB
• mrkr-20231231xex31d2.htm (EX-31.2) — 14KB
• mrkr-20231231xex32d1.htm (EX-32.1) — 8KB
• mrkr-20231231xex32d2.htm (EX-32.2) — 8KB
• mrkr-20231231xex97.htm (EX-97) — 41KB
• mrkr-20231231x10k001.jpg (GRAPHIC) — 15KB
• mrkr-20231231x10k002.jpg (GRAPHIC) — 46KB
• mrkr-20231231x10k003.jpg (GRAPHIC) — 34KB
• mrkr-20231231x10k004.jpg (GRAPHIC) — 34KB
• mrkr-20231231x10k005.jpg (GRAPHIC) — 36KB
• mrkr-20231231x10k006.jpg (GRAPHIC) — 73KB
• mrkr-20231231x10k007.jpg (GRAPHIC) — 99KB
• mrkr-20231231xex4d0001.jpg (GRAPHIC) — 434KB
• mrkr-20231231xex4d0002.jpg (GRAPHIC) — 86KB
• 0001410578-24-000297.txt (&nbsp;) — 9621KB
• mrkr-20231231.xsd (EX-101.SCH) — 52KB
• mrkr-20231231_cal.xml (EX-101.CAL) — 53KB
• mrkr-20231231_def.xml (EX-101.DEF) — 214KB
• mrkr-20231231_lab.xml (EX-101.LAB) — 438KB
• mrkr-20231231_pre.xml (EX-101.PRE) — 361KB
• mrkr-20231231x10k_htm.xml (XML) — 1078KB

FORWARD LOOKING STATEMENTS

FORWARD LOOKING STATEMENTS ii Part I Item 1.

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 28 Item 1B. Unresolved Staff Comments 67 Item 1C. Cybersecurity 68 Item 2.

Properties

Properties 69 Item 3.

Legal Proceedings

Legal Proceedings 69 Item 4. Mine Safety Disclosure 69 Part II Item 5. Market For Registrant's Common Equity, Related Stockholder Matters And Issuer Purchases Of Equity Securities 70 Item 6. [Reserved] 70 Item 7.

Management's Discussion And Analysis Of Financial Condition And Results Of Operations

Management's Discussion And Analysis Of Financial Condition And Results Of Operations 71 Item 7A.

Quantitative And Qualitative Disclosures About Market Risk

Quantitative And Qualitative Disclosures About Market Risk 83 Item 8.

Financial Statements

Financial Statements 83 Item 9. Changes In And Disagreements With Accountants On Accounting And Financial Disclosure 83 Item 9A.

Controls And Procedures

Controls And Procedures 84 Item 9B. Other Information 85 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 85 Part III Item 10. Directors, Executive Officers And Corporate Governance 86 Item 11.

Executive Compensation

Executive Compensation 86 Item 12.

Security Ownership Of Certain Beneficial Owners And Management And Related Stockholder Matters

Security Ownership Of Certain Beneficial Owners And Management And Related Stockholder Matters 86 Item 13. Certain Relationships And Related Transactions, And Director Independence 86 Item 14. Principal Accounting Fees And Services 86 Part IV Item 15. Exhibits, Financial Statement Schedules 87 Item 16. Form 10-K Summary 89

Signatures

Signatures 90 i Table of Contents CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS This annual report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part I, Item 1: "Business," Part I, Item 1A: "Risk Factors," and Part 2, Item 7: "Management's Discussion and Analysis of Financial Condition and Results of Operations," but are also contained elsewhere in this annual report. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms or other comparable terminology. These statements speak only as of the date of this Annual Report and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements in this annual report include statements as to: our ability to continue as a going concern; the timing, progress and results of clinical trials of multi tumor associated antigen ("multiTAA")-specific T cell therapies and our other product candidates, including statements regarding the timing of initiation and completion of preclinical studies or clinical trials or related preparatory work, the period during which the results of the trials wil

BUSINESS

ITEM 1. BUSINESS Overview We are a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. We developed our lead product candidates from our multi tumor associated antigen ("multiTAA")-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumor-associated antigens, or TAAs. This approach selectively expands tumor-specific T cells from a patient's/donor's blood and is able to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Targeting multiple antigens simultaneously exploits the natural capacity of T cells to recognize and kill tumor targets via native T cell receptors ("TCR"), while limiting tumor adaptation/escape by antigen-negative selection or antigen down-regulation. When infused into a patient with cancer, the multiTAA-specific T cells are designed to kill cancer cells expressing the TAA and potentially recruit the patient's immune system to participate in the cancer killing process. We licensed the underlying technology for multiTAA-specific T cell therapy from Baylor College of Medicine, or BCM, in March 2018. BCM had utilized the therapy in seven exploratory clinical trials. In these studies, BCM treated over 150 patients suffering from a variety of cancers including lymphoma, multiple myeloma, acute myeloid leukemia, or AML, acute lymphoblastic leukemia, or ALL, pancreatic cancer, breast cancer and various sarcomas. In those studies, BCM saw evidence of clinical benefit, expansion of infused cells, and decreased toxicity compared to other cellular therapies. We are advancing two product candidates for 3 clinical indications as part of our multiTAA-specific T cell program for: Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) Off-the-Shelf (OTS) product in vari

View Full Filing

View this 10-K filing on SEC EDGAR